Peptide Drug

DRAVP ID DRAVPc072

Name Tocilizumab

Sequence >Tocilizumab light chain: DIQMTQSPSSLSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSRLHSGVPS RFSGSGSGTDFTFTISSLQPEDIATYYCQQGNTLPYTFGQGTKVEIKRTVAAPSVFIFPP SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT >Tocilizumab heavy chain: QVQLQESGPGLVRPSQTLSLTCTVSGYSITSDHAWSWVRQPPGRGLEWIGYISYSGITTY NPSLKSRVTMLRDTSKNQFSLRLSSVTAADTAVYYCARSLARTTAMDYWGQGSLVTVSSA STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPG LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Molecular Formula C6428H9976N1720O2018S42

Condition/Disease COVID-19

Group Approved

Type antibody

Description Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions.It was approved by Health Canada on 30 April 2010.11 After being investigated to treat severely ill patients with COVID-19,1,7,8 tocilizumab was approved by the European Commission in December 2021 to treat COVID-19 in adults receiving systemic corticosteroids and supplemental oxygen or mechanical ventilation.

Active sequence/Structure

DrugBank Accession Number DB06273

Pubchem ID 347910344

CHEMBL ID CHEMBL1237022

UNII I031V2H011

CAS 375823-41-9

Reference 27599663 25190079 20608753 12669473 32278585

NCT Number	Study Title	Condition/Disease	Status	Phase	Sponsor
NCT04363736	A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia (MARIPOSA)	COVID-19 Pneumonia	Completed	Phase 2	Hoffmann-La Roche
NCT04479358	Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19 (COVIDOSE-2)	COVID-19	Active, not recruiting	Phase 2	University of Chicago
NCT06033196	Tocilizumab in Lung Transplantation (ALL IN LUNG)	Lung Transplant	Recruiting	Phase 2	National Institute of Allergy and Infectious Diseases (NIAID)
NCT04361032	Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia (TRONCHER)	COVID19，Intensive Care Unit	Unknown status	Phase 3	Abderrahmane Mami Hospital
NCT04893031	Effect of Tocilizumab on Intensive Care Patients With COVID-19 Pneumonia, a Retrospective Cohort Study	COVID-19，Critical Care，Mortality	Completed		Karadeniz Technical University

NCT Number

Study Title

Condition/Disease

Status

Phase

Sponsor

NCT04363736

A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia (MARIPOSA)

COVID-19 Pneumonia

Completed

Phase 2

Hoffmann-La Roche

NCT04479358

Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19 (COVIDOSE-2)

COVID-19

Active, not recruiting

Phase 2

University of Chicago

NCT06033196

Tocilizumab in Lung Transplantation (ALL IN LUNG)

Lung Transplant

Recruiting

Phase 2

National Institute of Allergy and Infectious Diseases (NIAID)

NCT04361032

Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia (TRONCHER)

COVID19，Intensive Care Unit

Unknown status

Phase 3

Abderrahmane Mami Hospital

NCT04893031

Effect of Tocilizumab on Intensive Care Patients With COVID-19 Pneumonia, a Retrospective Cohort Study

COVID-19，Critical Care，Mortality

Completed

Karadeniz Technical University